

# Matthew R Gardner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8556636/publications.pdf>

Version: 2024-02-01

21  
papers

873  
citations

623699

14  
h-index

752679

20  
g-index

22  
all docs

22  
docs citations

22  
times ranked

1380  
citing authors

#	ARTICLE	IF	CITATIONS
1	AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. <i>Nature</i> , 2015, 519, 87-91.	27.8	265
2	Associating HIV-1 envelope glycoprotein structures with states on the virus observed by smFRET. <i>Nature</i> , 2019, 568, 415-419.	27.8	156
3	Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2. <i>PLoS Pathogens</i> , 2021, 17, e1009501.	4.7	97
4	Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies. <i>Molecular Therapy</i> , 2019, 27, 650-660.	8.2	42
5	AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	35
6	A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies. <i>MBio</i> , 2020, 11, .	4.1	27
7	Enhanced Recognition and Neutralization of HIV-1 by Antibody-Derived CCR5-Mimetic Peptide Variants. <i>Journal of Virology</i> , 2012, 86, 12417-12421.	3.4	24
8	eCD4-Ig promotes ADCC activity of sera from HIV-1-infected patients. <i>PLoS Pathogens</i> , 2017, 13, e1006786.	4.7	24
9	eCD4-Ig Variants That More Potently Neutralize HIV-1. <i>Journal of Virology</i> , 2018, 92, .	3.4	22
10	Conditional Regulation of Gene Expression by Ligand-Induced Occlusion of a MicroRNA Target Sequence. <i>Molecular Therapy</i> , 2018, 26, 1277-1286.	8.2	22
11	Promise and Progress of an HIV-1 Cure by Adeno-Associated Virus Vector Delivery of Anti-HIV-1 Biologics. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 176.	3.9	22
12	eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody. <i>Journal of Virology</i> , 2019, 93, .	3.4	19
13	Engineering antibody-like inhibitors to prevent and treat HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 294-301.	3.8	18
14	Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies. <i>PLoS Pathogens</i> , 2018, 14, e1007238.	4.7	18
15	A Double-Mimetic Peptide Efficiently Neutralizes HIV-1 by Bridging the CD4- and Coreceptor-Binding Sites of gp120. <i>Journal of Virology</i> , 2014, 88, 3353-3358.	3.4	14
16	CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies. <i>Journal of Virology</i> , 2016, 90, 7822-7832.	3.4	14
17	High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 24, 199-206.	4.1	13
18	Direct Expression and Validation of Phage-selected Peptide Variants in Mammalian Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 18803-18810.	3.4	10

#	ARTICLE	IF	CITATIONS
19	Simian Immunodeficiency Virus SIVmac239, but Not SIVmac316, Binds and Utilizes Human CD4 More Efficiently than Rhesus CD4. <i>Journal of Virology</i> , 2017, 91, .	3.4	3
20	A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies. <i>Journal of Virology</i> , 2019, 93, .	3.4	2
21	Estimation of the in vivo neutralization potency of eCD4lg and conditions for AAV-mediated production for SHIV long-term remission. <i>Science Advances</i> , 2022, 8, eabj5666.	10.3	1